Probiodrug pursues modified abeta approach to tackle Alzheimer's- Dr. Konrad Glund, CEO, Probiodrug 00:00:00

Share On Facebook Share On Twitter

Probiodrug AG CEO Dr. Konrad Glund tells Mike Ward, global director of content for Informa's pharma insights portfolio, about his company's differentiated approach to targeting Alzheimer's disease.

Recent Videos